公开(公告)号：US6162898A

公开(公告)日：2000-12-19

申请号：US138069

申请日：1998-08-21

Applicant: Bryan R. Cullen

Inventor： Bryan R. Cullen

IPC: A61K38/00 ,  C07K14/15 ,  C07K14/16 ,  C07K16/10 ,  C12N15/49 ,  G03C7/30 ,  G03C7/36 ,  C07K14/00

CPC classification number: C07K14/005 ,  A61K38/00 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10043 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12N2740/16322 ,  G03C7/3013 ,  G03C7/36

Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. And in some cases both the Rev and the Rex function and are, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1, infection.

Abstract translation: 衍生自HIV-1的rev基因产物或HTLV-1的rex基因产物和相应的突变基因的具有抑制HIV-1中Rev功能和/或Rex功能的能力的病毒基因表型表达的显性阻遏物 HTLV-I和HTLV-II。 在某些情况下，Rev和Rex的功能都是活跃在一种以上的病毒物种中。 这样的显性病毒突变体可用作抗病毒剂，例如这些跨主导抑制剂可用于诸如细胞内免疫的治疗方法中，以保护细胞免受病毒的有害影响，例如， HIV-1，感染。

公开(公告)号：US6136319A

公开(公告)日：2000-10-24

申请号：US013760

申请日：1998-01-27

Applicant: Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

Inventor： Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61P31/12 ,  A61P37/04 ,  C07K16/08 ,  C07K16/10 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61K39/44

CPC classification number: C07K16/1036 ,  A61K39/12 ,  C07K16/08 ,  C07K16/081 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  A61K38/00 ,  A61K39/00 ,  C12N2720/10034 ,  Y10S435/948

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

Abstract translation: 在动物对象中产生针对病毒性疾病的主动免疫的方法包括向受试者施用基本上由活病毒和与活病毒结合的中和因子组成的疫苗缀合物。 中和因子选自抗体和抗体片段。 活病毒是能够在受试者中产生疾病的活病毒，抗体或抗体片段是能够中和活病毒的物质。 优选的受试者是鸟，优选的病毒是传染性法氏囊病病毒，并且向鸟类施用的优选途径是通过卵内施用。

公开(公告)号：US5871933A

公开(公告)日：1999-02-16

申请号：US483353

申请日：1995-06-07

Applicant: Gregory R. Reyes ,  Kenneth G. Hadlock

Inventor： Gregory R. Reyes ,  Kenneth G. Hadlock

IPC: A61K39/12 ,  A61K38/00 ,  A61K39/00 ,  A61P31/12 ,  C07K1/22 ,  C07K7/06 ,  C07K7/08 ,  C07K14/15 ,  C07K16/00 ,  C07K16/10 ,  C12N1/21 ,  C12N15/09 ,  C12P21/02 ,  C12R1/19 ,  G01N33/53 ,  G01N33/574 ,  G01N33/577 ,  A61K39/21 ,  C12Q1/68

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2740/14022 ,  Y10S435/974 ,  Y10S435/975

Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.

Abstract translation: 公开了新型HTLV-1和HTLV-II肽抗原用于筛选和确认HTLV-1和HTLV-II抗血清的诊断测定。 肽衍生自HTLV-1和HTLV-II gp46包膜蛋白的类似区域，并通过其与HTLV-II特异性单克隆抗体和HTLV-I和HTLV-II抗血清的免疫反应性来区分。 肽也可用于疫苗组合物。

公开(公告)号：US5871748A

公开(公告)日：1999-02-16

申请号：US697268

申请日：1996-08-21

Applicant: Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

Inventor： Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61P31/12 ,  A61P37/04 ,  C07K16/08 ,  C07K16/10 ,  A61K39/15 ,  C07K16/00 ,  C12N1/00 ,  C12N7/00

CPC classification number: C07K16/1036 ,  A61K39/12 ,  C07K16/08 ,  C07K16/081 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  A61K38/00 ,  A61K39/00 ,  C12N2720/10034 ,  Y10S435/948

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

公开(公告)号：US5827750A

公开(公告)日：1998-10-27

申请号：US708107

申请日：1996-08-08

Applicant: Sidney E. Grossberg ,  Vladimir M. Kushnaryov ,  L. William Cashdollar ,  Donald R. Carrigan ,  Konstance K. Knox

Inventor： Sidney E. Grossberg ,  Vladimir M. Kushnaryov ,  L. William Cashdollar ,  Donald R. Carrigan ,  Konstance K. Knox

IPC: A61K39/21 ,  C07K14/15 ,  C07K16/10 ,  C12N7/00 ,  G01N33/569 ,  G01N33/53 ,  C12N5/00 ,  G01N33/531

CPC classification number: G01N33/56983 ,  C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N2740/10021 ,  C12N2740/10022

Abstract: A method for the detection of the presence or absence of antibodies which bind to antigens of an NMA virus indicative of Chronic Fatigue Immune Deficiency Syndrome is disclosed. This method comprises contacting a solution containing antigens of an NMA virus with a biological sample of a patient and detecting the antibody-antigen complexes. Methods for detection of the presence or absence of antigens or nucleic acid sequences specific to an NMA virus are also disclosed. A substantially purified preparation of an NMA virus and a human cell line chronically infected with an NMA virus are also disclosed.

Abstract translation: 公开了一种用于检测结合指示慢性疲劳免疫缺陷综合征的NMA病毒的抗原的抗体的存在或不存在的方法。 该方法包括将含有NMA病毒抗原的溶液与患者的生物样品接触并检测抗体 - 抗原复合物。 还公开了检测NMA病毒特异性的抗原或核酸序列的存在或不存在的方法。 还公开了NMA病毒和长期感染NMA病毒的人类细胞系的基本上纯化的制剂。

公开(公告)号：US5814441A

公开(公告)日：1998-09-29

申请号：US481598

申请日：1995-06-07

Applicant: Gregory R. Reyes ,  Kenneth G. Hadlock

Inventor： Gregory R. Reyes ,  Kenneth G. Hadlock

IPC: A61K39/12 ,  A61K38/00 ,  A61K39/00 ,  A61P31/12 ,  C07K1/22 ,  C07K7/06 ,  C07K7/08 ,  C07K14/15 ,  C07K16/00 ,  C07K16/10 ,  C12N1/21 ,  C12N15/09 ,  C12P21/02 ,  C12R1/19 ,  G01N33/53 ,  G01N33/574 ,  G01N33/577 ,  C12Q1/70 ,  G01N33/564 ,  G01N33/567

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2740/14022 ,  Y10S435/974 ,  Y10S435/975

Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.

公开(公告)号：US5397696A

公开(公告)日：1995-03-14

申请号：US743518

申请日：1991-08-12

Applicant: Richard Yanagihara ,  Vivek R. Nerurkar ,  Carol Jenkins ,  Mark Miller ,  Ralph M. Garruto

Inventor： Richard Yanagihara ,  Vivek R. Nerurkar ,  Carol Jenkins ,  Mark Miller ,  Ralph M. Garruto

IPC: A61K39/00 ,  C07K14/15 ,  C07K16/10 ,  C12N7/00 ,  C12N7/02

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  A61K39/00 ,  C12N2510/00 ,  C12N2740/14021 ,  C12N2740/14022

Abstract: The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian populations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.

Abstract translation: 本发明涉及持续感染巴布亚新几内亚（PNG）HTLV-1变体和感染病毒（PNG-1变体）的人T细胞系（PNG-1）。 本发明的细胞表达病毒抗原，C型粒子并具有低水平的逆转录酶活性。 这种细胞系的建立是来自巴布亚新几内亚的第一种细胞系，使得可以使用当地病毒株筛选美拉尼西亚人群。 本发明还涉及用于人类针对感染的疫苗和由HTLV-1和相关病毒引起的疾病。 本发明还涉及用于检测和诊断由HTLV-1和相关病毒引起的感染和疾病的各种生物测定和试剂盒。

公开(公告)号：US4855235A

公开(公告)日：1989-08-08

申请号：US758224

申请日：1985-07-08

Applicant: Toshitada Takahashi ,  Ryuzo Ueda ,  Kazuo Ohta

Inventor： Toshitada Takahashi ,  Ryuzo Ueda ,  Kazuo Ohta

IPC: G01N33/577 ,  A61K39/395 ,  C07K14/005 ,  C07K14/15 ,  C07K14/195 ,  C07K16/00 ,  C07K16/10 ,  C07K16/30 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/569

CPC classification number: G01N33/56972 ,  C07K16/1036 ,  C07K16/3061 ,  Y10S436/811 ,  Y10S530/864

Abstract: Monoclonal antibodies, Ta60b(Ferm BP-2170) and Ts145(Ferm BP-2171), are used for detecting human leukocyte antigens such as T cell differentiation antigens and T cell subset antigens.

Abstract translation: PCT No.PCT / JP84 / 00120 Sec。 371日期：1985年7月8日 102（e）日期1985年7月8日PCT提交1984年3月23日PCT公布。 出版物WO85 / 02188 日期：1985年5月23日。单克隆抗体Ta60b（Ferm BP-2170）和Ts145（Ferm BP-2171）用于检测人白细胞抗原如T细胞分化抗原和T细胞亚群抗原。

公开(公告)号：WO2011002936A2

公开(公告)日：2011-01-06

申请号：PCT/US2010/040676

申请日：2010-06-30

Applicant: ABBOTT LABORATORIES ,  THE CLEVELAND CLINIC FOUNDATION ,  QIU, Xiaoxing ,  DAS GUPTA, Jaydip ,  HACKETT, John, R. ,  LUK, Ka-Cheung, X. ,  SILVERMAN, Robert, H. ,  SWANSON, Priscilla

Inventor： QIU, Xiaoxing ,  DAS GUPTA, Jaydip ,  HACKETT, John, R. ,  SILVERMAN, Robert, H. ,  SWANSON, Priscilla

IPC: G01N33/53 ,  G01N33/574

CPC classification number: C07K16/1036 ,  A61K39/00 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C12N2740/13022

公开(公告)号：WO2006119527A3

公开(公告)日：2007-04-05

申请号：PCT/AT2006000197

申请日：2006-05-11

Applicant: GREENHILLS BIOTECHNOLOGY RES D ,  MAYER BERND ,  HUMER JOHANNES ,  MUSTER THOMAS

Inventor： MAYER BERND ,  HUMER JOHANNES ,  MUSTER THOMAS

IPC: A61K39/21 ,  A61K38/16

CPC classification number: A61K38/162 ,  A61K39/00 ,  C07K14/005 ,  C07K14/4748 ,  C07K16/1036 ,  C07K2317/34 ,  C12N2740/10022 ,  G01N33/5743 ,  G01N2333/15 ,  G01N2469/20

Abstract: The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.

Abstract translation: 本发明提供衍生自黑素瘤相关内源性逆转录病毒（MERV）的抗原多肽。 这些抗原是检测癌细胞和黑素瘤诊断以及黑素瘤预后的有用化合物。 此外，本发明的这些抗原多肽形成抗癌疫苗的基础。